Yuhan 過去の業績

過去基準チェック /56

Yuhanは、平均年間2.8%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間成長しています。収益は、平均年間7.8% 5.5%収益成長率で成長しています。 Yuhanの自己資本利益率は7.5%であり、純利益率は8.2%です。

主要情報

2.8%

収益成長率

2.0%

EPS成長率

Pharmaceuticals 業界の成長	11.3%
収益成長率	5.5%
株主資本利益率	7.5%
ネット・マージン	8.2%
前回の決算情報	30 Sep 2024

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

May 26

Recent updates

Yuhan Corporation (KRX:000100) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Nov 14

Is Yuhan (KRX:000100) Using Too Much Debt?

Oct 08

Estimating The Intrinsic Value Of Yuhan Corporation (KRX:000100)

Sep 16

Subdued Growth No Barrier To Yuhan Corporation (KRX:000100) With Shares Advancing 41%

Aug 28

Yuhan Corporation's (KRX:000100) Price In Tune With Earnings

Jul 01

Yuhan Corporation (KRX:000100) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jun 13

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

May 26

Here's Why Yuhan (KRX:000100) Can Manage Its Debt Responsibly

May 13

Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce

Mar 11

Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet

May 01

Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?

Apr 16

Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)

Mar 15

Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Feb 25

Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?

Feb 10

Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?

Jan 28

The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More

Jan 13

Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Nov 20

収支内訳

Yuhan の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

KOSE:A000100 収益、費用、利益 ( )KRW Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	2,008,841	165,686	384,162	197,701
30 Jun 24	1,893,119	147,849	385,446	146,919
31 Mar 24	1,860,529	124,466	378,998	130,975
31 Dec 23	1,858,984	133,993	370,027	119,920
30 Sep 23	1,872,336	88,109	365,050	117,355
30 Jun 23	1,820,811	76,045	350,511	114,124
31 Mar 23	1,808,041	101,446	355,579	111,826
31 Dec 22	1,775,847	95,144	356,575	107,103
30 Sep 22	1,749,315	74,669	359,069	116,405
30 Jun 22	1,769,245	97,836	362,073	112,866
31 Mar 22	1,719,630	97,911	355,095	108,107
31 Dec 21	1,687,810	102,583	346,977	106,677
30 Sep 21	1,725,261	98,128	350,567	121,027
30 Jun 21	1,703,475	97,833	333,638	128,767
31 Mar 21	1,685,623	97,578	321,279	141,056
31 Dec 20	1,619,865	192,761	309,459	142,634
30 Sep 20	1,552,188	184,730	292,514	124,020
30 Jun 20	1,504,765	168,667	292,671	109,357
31 Mar 20	1,448,677	140,227	291,603	96,264
31 Dec 19	1,480,354	40,006	298,249	96,900
30 Sep 19	1,500,782	44,230	295,958	84,846
30 Jun 19	1,497,130	41,438	289,460	86,652
31 Mar 19	1,523,954	52,333	285,113	81,152
31 Dec 18	1,518,823	57,481	272,199	74,067
30 Sep 18	1,481,906	70,146	260,112	78,217
30 Jun 18	1,482,034	84,572	255,011	72,563
31 Mar 18	1,450,870	100,288	254,545	70,132
31 Dec 17	1,462,248	109,034	251,733	71,435
30 Sep 17	1,434,749	139,325	247,128	63,536
30 Jun 17	1,417,835	137,434	242,253	60,608
31 Mar 17	1,395,518	139,440	233,210	57,434
31 Dec 16	1,320,797	161,249	228,048	52,667
30 Sep 16	1,274,011	134,997	229,655	50,435
30 Jun 16	1,223,925	155,819	221,368	48,078
31 Mar 16	1,163,130	152,682	209,371	43,881
31 Dec 15	1,128,731	126,047	206,756	39,016
30 Sep 15	1,097,229	118,104	199,135	34,597
30 Jun 15	1,046,716	98,362	199,297	30,754
31 Mar 15	1,031,875	94,628	202,271	31,270
31 Dec 14	1,017,492	90,948	202,259	30,915
30 Sep 14	1,007,109	95,434	200,307	31,018
30 Jun 14	970,253	87,696	192,807	31,896
31 Mar 14	953,191	83,863	193,993	31,378
31 Dec 13	943,609	86,461	192,515	32,027

質の高い収益: A000100は高品質の収益を持っています。

利益率の向上: A000100の現在の純利益率 (8.2%)は、昨年(4.7%)よりも高くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: A000100の収益は過去 5 年間で年間2.8%増加しました。

成長の加速: A000100の過去 1 年間の収益成長率 ( 88% ) は、5 年間の平均 ( 年間2.8%を上回っています。

収益対業界: A000100の過去 1 年間の収益成長率 ( 88% ) はPharmaceuticals業界20.6%を上回りました。

株主資本利益率

高いROE: A000100の自己資本利益率 ( 7.5% ) は低いとみなされます。

Yuhan 過去の業績

過去 基準チェック /56

主要情報

最近の業績更新

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

Full year 2023 earnings released: EPS: ₩1,815 (vs ₩1,267 in FY 2022)

First quarter 2023 earnings released: EPS: ₩311 (vs ₩222 in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS ₩470 (vs ₩464 in 3Q 2020)

Recent updates

Dividend of ₩429 announced

Yuhan Corporation (KRX:000100) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Is Yuhan (KRX:000100) Using Too Much Debt?

Price target increased by 8.1% to ₩110,188

Price target increased by 7.9% to ₩108,412

Investor sentiment improves as stock rises 17%

Estimating The Intrinsic Value Of Yuhan Corporation (KRX:000100)

Investor sentiment improves as stock rises 44%

Subdued Growth No Barrier To Yuhan Corporation (KRX:000100) With Shares Advancing 41%

Price target increased by 7.1% to ₩99,222

Investor sentiment deteriorates as stock falls 15%

Now 20% undervalued

Investor sentiment improves as stock rises 15%

Yuhan Corporation's (KRX:000100) Price In Tune With Earnings

Yuhan Corporation (KRX:000100) Shares Could Be 37% Below Their Intrinsic Value Estimate

Investor sentiment improves as stock rises 19%

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

Consensus revenue estimates increase by 28%

Here's Why Yuhan (KRX:000100) Can Manage Its Debt Responsibly

Now 22% overvalued after recent price rise

Full year 2023 earnings released: EPS: ₩1,815 (vs ₩1,267 in FY 2022)

Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce

Investor sentiment improves as stock rises 18%

Insufficient new directors

Now 21% undervalued

Upcoming dividend of ₩381 per share at 0.6% yield

Consensus EPS estimates increase by 37%, revenue downgraded

Investor sentiment deteriorates as stock falls 23%

Now 24% undervalued

Price target increased by 7.8% to ₩80,222

First quarter 2023 earnings released: EPS: ₩311 (vs ₩222 in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued after recent price drop

Upcoming dividend of ₩381 per share

Consensus EPS estimates fall by 11%

Now 20% undervalued

Full year 2021 earnings: EPS and revenues miss analyst expectations

Yuhan Corporation (KOSE:A000100) announces an Equity Buyback for KRW 20,000 million worth of its shares.

Upcoming dividend of ₩381 per share

Third quarter 2021 earnings released: EPS ₩470 (vs ₩464 in 3Q 2020)

First quarter 2021 earnings released: EPS ₩315 (vs ₩1,768 in 1Q 2020)

Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet

Consensus forecasts updated

Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?

Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)

Full year 2020 earnings released: EPS ₩2,943 (vs ₩610 in FY 2019)

New 90-day low: ₩60,700

Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Yuhan Corporation, Annual General Meeting, Mar 19, 2021

Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?

Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?

The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More

New 90-day high: ₩75,100

Is Yuhan Corporation (KRX:000100) Popular Amongst Institutions?

New 90-day high: ₩75,100

Estimating The Fair Value Of Yuhan Corporation (KRX:000100)

New 90-day high: ₩72,300

Is Yuhan Corporation's (KRX:000100) 0.6% Dividend Worth Your Time?

Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Price target raised to ₩72,704

Price target raised to ₩67,579

Yuhan Corporation and Sorrento Therapeutics, Inc. Announces Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

New 90-day high: ₩72,000

Price target raised to ₩63,148

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

過去基準チェック /56